Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

John Quinn

Neurological Surgery Houston, TX Medical Doctor

NPI 1053587865 CMS profile 319852

920 Frostwood Dr Ste 2.300, Houston, TX 77024

Open in the dashboard

General payments

$21,899

266 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, John Quinn of Houston, TX is reported in the CMS Open Payments database as having received $21,899 across 266 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 79th percentile of Neurological Surgery profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $7,774 79
2024 General $4,852 81
2023 General $1,761 9
2022 General $2,325 19
2021 General $2,356 28
2020 General $1,828 22
2019 General $1,004 28

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • John Quinn
  • Neurological Surgery median
  • Middle half of Neurological Surgery
  • National median

In program year 2025, general payments to John Quinn were reported at $7,774. Among 5,467 Neurological Surgery profiles paid that year, the median was $596 and the middle half received between $159 and $3,102.

Show as a table
Year John Quinn Neurological Surgery median Middle half National median
2019 $1,004 $582 $138–$3,006 $163
2020 $1,828 $294 $76–$2,174 $114
2021 $2,356 $387 $105–$2,432 $132
2022 $2,325 $542 $139–$2,989 $149
2023 $1,761 $534 $145–$2,697 $160
2024 $4,852 $574 $155–$3,046 $164
2025 $7,774 $596 $159–$3,102 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. NuVasive, Inc. $5,389 58 payments
  2. Alphatec Spine, Inc $4,417 21 payments
  3. Globus Medical, Inc. $3,867 103 payments
  4. Stryker Corporation $1,767 9 payments
  5. DePuy Synthes Sales Inc. $1,103 16 payments
  6. Smaio USA Corporation $1,048 2 payments
  7. SI-BONE, Inc. $953 25 payments
  8. Smaio SA $911 6 payments
  9. Medtronic, Inc. $525 5 payments
  10. icotec Medical Inc. $425 2 payments
  11. Other $1,495 19 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $10,878 218 payments
  2. Travel and Lodging $9,971 46 payments
  3. Consulting Fee $1,050 2 payments
Products named General payments · program years 2019–2025
  1. Other - Miscellaneous $3,786 17 payments
  2. XLIF $2,330 17 payments
  3. RELINE Spine/Spine Surgery $1,780 42 payments
  4. RELINE Spine/Spine Surgery $1,670 17 payments
  5. EVEREST SPINAL SYSTEM $1,160 4 payments
  6. ALIF $1,050 2 payments
  7. Teligen $824 10 payments
  8. Pulse $753 4 payments
  9. Invictus OPEN $631 4 payments
  10. SABLE $512 19 payments
  11. Other $7,173 151 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 8 drugs

Part D claims

465

Median for Neurosurgery: 83

Drug cost

$8,575

Median for Neurosurgery: $872

Branded share of claims

30.8%

Median for Neurosurgery: 16.5%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Celecoxib Generic 142 $4,851
Pregabalin Generic 47 $1,069
Hydrocodone-Acetaminophen Hydrocodone/Acetaminophen Brand 116 $1,061
Gabapentin Generic 71 $910
Methocarbamol Generic 35 $322
Oxycodone-Acetaminophen Oxycodone Hcl/Acetaminophen Brand 27 $195
Cyclobenzaprine Hcl Generic 12 $95
Methylprednisolone Generic 15 $72

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 2,779 Part D prescribers listed as Neurosurgery; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 59 billing codes

Paid by Medicare

$282,791

Medicare's payments for the services billed

Medicare patients

241

Average age 73

Services billed

871

131 women, 110 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 75%
Osteoporosis 42%
Diabetes 37%
Ischemic heart disease 35%
Depression 34%
Chronic kidney disease 25%
Heart failure 17%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

266 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Neurological Surgery in Texas

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record